drugset / Trial / NCT01926639

Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma

NCT01926639 ↗

NaSingle-groupOpen-labelTreatment

Summary

Patients with non-curable disseminated follicular lymphoma receive local radiotherapy targeting single lymph nodes and injection of low-dose rituximab (anti-CD20) and autologous dendritic cells. The therapy is repeated 3 times, targeting different lesion. Aims are to induce tumor immunity and clinical responses.

Timeline

Start
2009-10
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 5 mg Other
Subject Rituximab Monoclonal antibody — Other

Indications